Introduction
Treatment of classical Hodgkin's disease (HD) is one of the successful stories in hematology. Since the introduction of ABVD regimen in 1970s, the results of treatment are constantly improving [1] . Even only aft er ABVD regimen administered for advanced disease stages the overall survival in large patient cohorts is 78%, however freedom from disease is only 66% [2] , indicating the need for high-dose chemotherapy for approximately 35% of patients. Th is led to development of more intensive protocols, like BECOPP [3] , and subsequently BEACOPPescalated and BEACOPP14 [4] that produced failure-free-survival (FFS) of 85-89% in advanced HD. Nonetheless these intensifi ed approaches were associated with signifi cant incidence of secondary malignancies [5, 6] as well as both male and female infertility [7] . Th is is the reason why several developed countries like the US, ABVD remains the standard of care for all disease stages [8] .
Th e eff orts to overcome the limitation of BEACOPP regimens were done aft er introduction of positron-emission tomography (PET) into clinical practice. It was demonstrated that PET status aft er two courses of chemotherapy strongly predict the outcome of treatment [9] . Th is fi nding was the foundation of several escalation studies [10, 11] where absence of complete response led to switching therapy from ABVD to BEACOPPesc. Also several de-escalation studies were lunched, where complete response based on PET triggered change of therapy from BEACOPPesc to ABVD [12] . Th ese two approaches were used as the basis for protocol development by Russian North West Oncology and Hematology Group (RNWOHG).
In Russian Federation around 3200 cases of HD are documented annually, which translates into 2.2 cases per 100000 people per year. Th e mortality from HD is 28,3% [13] , which is signifi cantly higher than reported in the foreign registry studies. Th ere might be several reasons for that: large distances between towns, poor excess to high-technology care, like second-line chemotherapy, autologous and allogeneic stem cell transplantation (auto and allo SCT), poor capabilities for supportive care in some of the oncology and hematology departments. In this study we wanted to solve several of these issues: coordinate the transfer of patients for the second line and to develop low toxicity protocol with relative high FFS aft er the fi rst line therapy.
Rationale and study design
Th e study upon diagnosis separates the patients into two groups: favorable prognosis and unfavorable prognosis. Th e defi nition of favorable is diff erent from the one of the German Hodgkin Study Group (GHSG). In this study presence stage IIB, large mediastinal mass, ESR more than 50 mm/h and IPS [2] more than 2 places a patient into unfavorable group, while stages I-IIA without these factors are considered favorable. Th e reason for that is the planned omission of radiotherapy in the PET(-) patients and truncation of therapy to 4 ABVD cycles in the group with partial response aft er two cycles. Th us we wanted to exclude the majority of patients who will fail this tapered therapy in the favorable arm ( Fig. 1) .
Th e treatment in the favorable arm includes two cycles of ABVD. Aft er that the therapy is selected based on the PET status. Patients with PET(-) CR go into follow up. Th is decision is based on the two studies: HD10 trial and NCIC CTG-ECOG HD.6 trial [14, 15] . Th e fi rst study demonstrates that 2xABVD are equivalent two 4xABVD with subsequent radiation therapy and the second that radiation therapy could be omitted aft er 4xABVD. Th ese were not PET-guided studies. We believe that strict selection of good prognosis patients and verifi cation of PET(-) status before end of therapy will produce the same results as in these two studies. Patients achieving PET(+) partial response undergo subsequent 2xABVD courses and radiation therapy, which the standard approach for the low risk responding well to the chemotherapy, used for example in HD10 study [14] . Patients that will have less then partial response aft er 2xABVD are switched to 4xBEACOPPesc or 4xBEACOPP14 according investigator choice. Th e effi cacy of this approach was tested in the study by Johnson et al. and Italian RATHL trial [10, 16] . In these two trials the FFS was more than 70% in all risk and stage groups, thus in the favorable group the FFS is expected to be more than 80%. Th e omission of radiotherapy aft er 4xBEA-COPPesc is based on GHSG HD12 trial, where there was no diff erence in FFS between radiotherapy and stop therapy groups [17] . In conclusion, based on the current data available the suggested approach should produce around 80-85% FFS in the favorable group.
Th e decision to leave BEACOPPesc or BEACOPP14 to an investigator choice is based on many consultations with participating centers. Several of them, which treat HD in inpatient setting were not willing to participate if there will be no option for BEACOPPesc, the other which predominantly treat HD in the outpatient setting were not willing to participate, if there will no option of BEACOPP14, because it is much better tolerated and could be reproduced in the outpatient facilities. In HD14 trial it was demonstrated that these two approaches are equivalent in terms of FFS [4] .
Th us in the unfavorable group the therapy is started from 2xBEACOPPesc or 2xBEACOPP14 according investigator choice. In PET(-) patients the de-escalation to ABVD/AVD cycles is planned. Th is is based on HD12 study, where without PET guidance switch to 4xABVD from 4xBEACOPPesc was not compromising the results, on study by Aviqdor et al. [18] , and on the randomized study by Johnson et al. where in PET (-) patients there was no diff erence between ABVD and AVD. Th is is the only randomization present in the study. Th e expected effi cacy of this approach is 85% FFS [10] . Patients who are PET(+) aft er two cycles continue BEACOP-Pesc/BEACOPP14 therapy up to 6 cycles. It is demonstrated in HD18 trial that the FFS is not compromised in PET(+) patients when they continued up to 8 BEACOPPesc courses [19] . In our study the therapy is limited two six cycles. Th is is based on the decision of opinion leaders from the participating centers. Radiation therapy is omitted aft er BEACOPPesc on the same basis as in the favorable arm of the study [17] . In conclusion, the unfavorable arm 1-st line is also expected to produce 80-85% FFS.
In the second line therapy four types of treatment is chosen by the investigator: DHAP, ICE, IGEV and brentuximab+ CTT JOURNAL | VOLUME 6 | NUMBER 4 | DECEMBER 2017 bendamustine (BB). Th ere are no restrictions in the choice of therapy since there are no large prospective randomized trials addressing this issue [20] . For patients with primary IPS ≥4 and primary refractory disease the BB second line is recommended because the effi cacy of standard approach with autoSCT results only in 9% FFS in this group of patients, while BB protocol seems to induce higher proportion of complete responses [21] [22] [23] . Th e third line includes only BB re-induction and mandatory alloSCT from related, unrelated or haploidentical donor, whoever is available.
Statistical considerations and expected results
Th e study is completed with observation program which will include patients treated with conventional approaches in the participating centers. Th us it is planned to compare the re- 
HIV-infected patients
Th e RNWOHG-HD1 program has the sub-study for HIV-infected patients. Since BEACOPPesc is poorly tolerated in this population of patients and results in 7% mortality [24] , all treatment in the fi rst line is based on ABVD courses with subsequent de-escalation to randomized ABVD/AVD cycles as in the general protocol ( Figure 2) . Th e 2 nd and 3 rd line therapies are identical to the general protocol. Th e protocol encourages the attending physicians to control the continuation of HAART therapy throughout the whole treatment process.
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Conclusion
In conclusion, the study is expected to improve the treatment practices in one region of Russian Federation. It is also expected to answer the questions of possible truncation of therapy based on prognostic factors and interim PET-assessed response.
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Многоцентровое проспективное эскалационнодеэскалационное исследование с ПЭТ контролем при классической лимфоме Ходжкина в Северо-Западном Федеральном Округе Российской Федерации (RNWOHG-HD1): обоснование и дизайн Резюме В настоящий момент на территории Российской Федерации (РФ) отсутствует стандарт лечения лимфомы Ходжкина (ЛХ). Летальность от ЛХ в РФ составляет 28,3%, что свидетельствует о необходимости улучшения качества оказания медицинской помощи. В данной статье приведено описание и обоснование проспективного кооперативного исследования RNWOHG-HD1, инициированного в Северо-Западном регионе РФ. Обсуждаются ключевые моменты протокола, включая эскалацию терапии с ABVD до BEACOPPesc в случае ПЭТ-позитивности после двух циклов в группе благоприятного прогноза, и деэскалация с BEACOPPesc до AVD/ ABVD в варианте рандомизации в случае достижения ПЭТ-негативного статуса в группе неблагопри-ятного прогноза. Протокол также подразумевает координацию медицинской помощи с целью получения пациентами доступа к второй и третьей линиям терапии, включая брентуксимаб, а также доступ к аутологичной и аллогенной трансплантации гемопоэтических стволовых клеток.
